988
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Mechanistic studies on human N-acetylgalactosamine kinase

&
Pages 370-376 | Received 06 Apr 2009, Accepted 27 May 2009, Published online: 29 Oct 2009

Figures & data

Figure 1. (a) The reaction catalyzed by N-acetylgalactosamine kinase. (b) The active site of GALK2. Only the substrates and key residues are shown. The loop comprising Thr-184 to Gly-186 accommodates the N-acetyl group of N-acetylgalactosamine (GalNAc). In galactokinase, the threonine and glycine residues in this loop are substituted for bulkier methionine and cysteine side chains respectively. Asp-190 is located with the carboxyl group in between the C1-OH of the sugar and the γ-phosphate of the nucleotide. This residue is likely to be important in the catalytic mechanism of the enzyme and its ionization state is probably influenced by Arg-43. The figure was drawn using PyMol (www.pymol.org) and the PDB file 2A2DCitation8. (c) Structures of N-acetylgalactosamine kinase inhibitors used in this study.

Figure 1.  (a) The reaction catalyzed by N-acetylgalactosamine kinase. (b) The active site of GALK2. Only the substrates and key residues are shown. The loop comprising Thr-184 to Gly-186 accommodates the N-acetyl group of N-acetylgalactosamine (GalNAc). In galactokinase, the threonine and glycine residues in this loop are substituted for bulkier methionine and cysteine side chains respectively. Asp-190 is located with the carboxyl group in between the C1-OH of the sugar and the γ-phosphate of the nucleotide. This residue is likely to be important in the catalytic mechanism of the enzyme and its ionization state is probably influenced by Arg-43. The figure was drawn using PyMol (www.pymol.org) and the PDB file 2A2DCitation8. (c) Structures of N-acetylgalactosamine kinase inhibitors used in this study.

Figure 2. Purification of recombinant human GALK2. Samples taken during the purification procedure (see methods) were analyzed by 10% SDS-PAGE. The sizes of molecular mass markers (M) are shown on the left. U, extract from cells prior to induction; I, extracts from induced cells prior to harvesting by centrifugation; S, protein solution extracted from cells by sonication and clarified by centrifugation; F, material which passed through the nickel–agarose column; E, protein eluted from this column in the presence of 250 mM imidazole.

Figure 2.  Purification of recombinant human GALK2. Samples taken during the purification procedure (see methods) were analyzed by 10% SDS-PAGE. The sizes of molecular mass markers (M) are shown on the left. U, extract from cells prior to induction; I, extracts from induced cells prior to harvesting by centrifugation; S, protein solution extracted from cells by sonication and clarified by centrifugation; F, material which passed through the nickel–agarose column; E, protein eluted from this column in the presence of 250 mM imidazole.

Figure 3. Recombinant human GALK2 (50 nM) is an active N-acetylgalactosamine kinase. In (a), the concentration of ATP was maintained at a constant level of 0.5 mM and N-acetylgalactosamine (GalNAc) was varied. The resulting data were fit (i) to the Michaelis–Menten equation (giving values of Km,GalNAc = 40 ± 14 μM and kcat = 1.0 ± 0.1 s−1) and (ii) to a modified version of this equation which accounts for substrate inhibition (giving values of Kis = 13 ± 8 mM, Km = 73 ± 27 mM, and kcat = 1.2 ± 0.1 s−1). In (b) the GalNAc concentration was maintained at 5 mM and the concentration of ATP was varied (giving values of Km,ATP = 14 ± 3 μM and kcat = 1.0 ± 0.1 s−1). Each point represents the mean of two or three separate determinations and the error bars the standard deviations of these means.

Figure 3.  Recombinant human GALK2 (50 nM) is an active N-acetylgalactosamine kinase. In (a), the concentration of ATP was maintained at a constant level of 0.5 mM and N-acetylgalactosamine (GalNAc) was varied. The resulting data were fit (i) to the Michaelis–Menten equation (giving values of Km,GalNAc = 40 ± 14 μM and kcat = 1.0 ± 0.1 s−1) and (ii) to a modified version of this equation which accounts for substrate inhibition (giving values of Kis = 13 ± 8 mM, Km = 73 ± 27 mM, and kcat = 1.2 ± 0.1 s−1). In (b) the GalNAc concentration was maintained at 5 mM and the concentration of ATP was varied (giving values of Km,ATP = 14 ± 3 μM and kcat = 1.0 ± 0.1 s−1). Each point represents the mean of two or three separate determinations and the error bars the standard deviations of these means.

Figure 4. The inhibition of GALK2 (50 nM) by α-methylgalactopyranoside. Inhibition was studied over a range of α-methylgalactopyranoside concentrations and three different ATP concentrations: 8 μM (inverted triangles, ▾), 15 μM (squares, ▪), and 60 μM (upright triangles, ▴). (a) In a Dixon plot the lines do not converge, suggesting that the inhibition is not competitive. (b) The converging lines on a plot of [ATP]/rate against [inhibitor] suggest that the mode of inhibition is uncompetitive with respect to ATP. In all cases the N-acetylgalactosamine concentration was 1.0 mM.

Figure 4.  The inhibition of GALK2 (50 nM) by α-methylgalactopyranoside. Inhibition was studied over a range of α-methylgalactopyranoside concentrations and three different ATP concentrations: 8 μM (inverted triangles, ▾), 15 μM (squares, ▪), and 60 μM (upright triangles, ▴). (a) In a Dixon plot the lines do not converge, suggesting that the inhibition is not competitive. (b) The converging lines on a plot of [ATP]/rate against [inhibitor] suggest that the mode of inhibition is uncompetitive with respect to ATP. In all cases the N-acetylgalactosamine concentration was 1.0 mM.

Figure 5. The effects of pH on the turnover number, kcat. The GALK2 concentration was 230 nM in these experiments. The line represents a fit to the equation kcat = kcat,lim(1 + [H+]/Ka1 + Ka2/[H+]).

Figure 5.  The effects of pH on the turnover number, kcat. The GALK2 concentration was 230 nM in these experiments. The line represents a fit to the equation kcat = kcat,lim(1 + [H+]/Ka1 + Ka2/[H+]).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.